Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$140.65 USD

140.65
787,033

-0.89 (-0.63%)

Updated Oct 31, 2025 03:59 PM ET

After-Market: $140.60 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 243)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now

by Zacks Equity Research

FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.

Zacks Equity Research

Here's Why You Should Add OPKO Health Stock to Your Portfolio

by Zacks Equity Research

OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.

Zacks Equity Research

WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit

by Zacks Equity Research

West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.

Zacks Equity Research

Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions

by Zacks Equity Research

HNST, BROS, AIM, MASI, and CTSH are spotlighted as top-ranked stocks with rising P/E ratios and strong earnings momentum.

Zacks Equity Research

GEHC Stock Up Following Approval to Boost Hemodynamic Monitoring

by Zacks Equity Research

GE HealthCare secures CE mark for Carevance, advancing scalable, cost-effective monitoring across care settings.

Sanghamitra Saha headshot

Bet On 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap these five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are The Honest Company, Dutch Bros, AIM ImmunoTech, Masimo and Cognizant Technology Solutions.

Zacks Equity Research

HIMS Stock Declines Despite Launch of New Specialty in Women's Health

by Zacks Equity Research

Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.

Zacks Equity Research

BDX Launches AI-Enabled Platform to Unify Healthcare Connectivity

by Zacks Equity Research

BD's new AI-driven Incada Platform and upgraded Pyxis Pro system unite connected care, driving its digital healthcare edge.

Zacks Equity Research

Here's Why Masimo (MASI) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Avantor Partners With BlueWhale Bio to Advance CAR-T Manufacturing

by Zacks Equity Research

AVTR collaborates with BlueWhale Bio to speed CAR-T manufacturing using CDNP tech, aiming to scale production and expand patient access.

Zacks Equity Research

Reasons to Add HealthEquity Stock to Your Portfolio for Now

by Zacks Equity Research

HQY's strong Q2, expanding HSAs and AI-driven efficiencies highlight its growth momentum despite data security risks.

Zacks Equity Research

Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition

by Zacks Equity Research

MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.

Zacks Equity Research

Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

by Zacks Equity Research

VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.

Zacks Equity Research

Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now

by Zacks Equity Research

WST's growth prospects remain strong, fueled by GLP-1 demand and high-value products, though tariffs and execution risks weigh on margins.

Zacks Equity Research

STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation

by Zacks Equity Research

Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.

Zacks Equity Research

BD Stock Down Despite Making Progress in the Treatment of PAD Lesions

by Zacks Equity Research

BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.

Zacks Equity Research

INSP Shares Down Despite Strong Clinical Data From Inspire V Trials

by Zacks Equity Research

Inspire Medical's Inspire V system shows strong safety, faster surgeries, and higher patient adherence in new trials.

Zacks Equity Research

Pulse Biosciences Unveils Promising First-in-Human Data for nPulse

by Zacks Equity Research

PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.

Zacks Equity Research

BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow

by Zacks Equity Research

BDX teams with Opentrons to automate single-cell sequencing, advancing its multiomics and biosciences strategy.

Zacks Equity Research

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.

Zacks Equity Research

GE Healthcare Partners With Erasmus to Advance Precision Cancer Care

by Zacks Equity Research

GEHC's collaboration with Erasmus MC aims to advance precision oncology using next-gen total body PET/CT and AI imaging innovations.

Zacks Equity Research

Ecolab Brings Direct-to-Chip Cooling Monitoring to Southeast Asia

by Zacks Equity Research

ECL debuts its 3D TRASAR direct-to-chip cooling monitoring in Singapore, boosting efficiency and sustainability in data centers.

Zacks Equity Research

OMI Reshapes Portfolio With $375 Million Sale to Platinum Equity

by Zacks Equity Research

Owens & Minor sharpens its focus on home-based care with a $375M divestiture to Platinum Equity, unlocking cash, tax benefits, and long-term upside through a retained equity stake.

Zacks Equity Research

The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock

by Zacks Equity Research

Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.

Zacks Equity Research

ISRG Shares Rise as FDA Clears AI Integration for Ion Platform

by Zacks Equity Research

Intuitive Surgical shares climb after FDA clears AI-driven upgrades for its Ion platform, boosting precision and efficiency in lung biopsies.